WallStSmart

Vicor Corporation (VICR)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vicor Corporation generates 65% more annual revenue ($426.70M vs $258.90M). VICR leads profitability with a 32.0% profit margin vs -15.5%. VICR earns a higher WallStSmart Score of 59/100 (C).

VICR

Buy

59

out of 100

Grade: C

Growth: 7.3Profit: 7.5Value: 4.0Quality: 7.8
Piotroski: 4/9Altman Z: 7.37

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for VICR.

ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VICR5 strengths · Avg: 9.4/10
Profit MarginProfitability
32.0%10/10

Keeps 32 of every $100 in revenue as profit

EPS GrowthGrowth
684.0%10/10

Earnings expanding 684.0% YoY

Altman Z-ScoreHealth
7.3710/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.5%9/10

Every $100 of equity generates 21 in profit

Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

VICR2 concerns · Avg: 3.0/10
Price/BookValuation
17.1x4/10

Trading at 17.1x book value

P/E RatioValuation
83.5x2/10

Premium valuation, high expectations priced in

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : VICR

The strongest argument for VICR centers on Profit Margin, EPS Growth, Altman Z-Score. Profitability is solid with margins at 32.0% and operating margin at 14.9%. Revenue growth of 20.2% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : VICR

The primary concerns for VICR are Price/Book, P/E Ratio. A P/E of 83.5x leaves little room for execution misses.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

VICR profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

VICR carries more volatility with a beta of 1.98 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor ELECTRONIC COMPONENTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VICR scores higher overall (59/100 vs 41/100), backed by strong 32.0% margins and 20.2% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Vicor Corporation

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Vicor Corporation designs, develops, manufactures, and markets modular power components and power systems to convert electrical power in the United States, Europe, Asia Pacific, and internationally. The company is headquartered in Andover, Massachusetts.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?